Schelter, Bjoern O

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 427

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 219

A longitudinal study of tremor frequencies in Parkinson’s disease and essential tremor

Hellwig, B., Mund, P., Schelter, B., Guschlbauer, B., Timmer, J., & Lücking, C. H. (2009) · Clinical Neurophysiology

Deep Brain Stimulation and Movement DisordersParkinson's Disease Mechanisms and Treatments

Cited by 65

Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Wischik, C. M., Bentham, P., Gauthier, S., Miller, S., Kook, K., & Schelter, B. O. (2022) · The Journal of Prevention of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 55